Author:
Turner Benjamin,Cree Bruce A. C.,Kappos Ludwig,Montalban Xavier,Papeix Caroline,Wolinsky Jerry S.,Buffels Regine,Fiore Damian,Garren Hideki,Han Jian,Hauser Stephen L.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference15 articles.
1. Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221–234
2. Papeix C, Cree B, Turner B et al (2017) Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the phase III OPERA I and OPERA II studies. In: 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting; 25–28 October 2017; Paris, France. Poster P687
3. Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302
4. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4:329–333
5. Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172–177
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献